Online testosterone therapy

The shape is consistent across reputable providers: an intake questionnaire, laboratory testing, a consultation with a licensed clinician, and — if testosterone is appropriate — a prescription dispensed by a pharmacy, followed by scheduled retesting.

The laboratory step is not optional and not a formality. A diagnosis here rests on measured levels, usually on more than one occasion and drawn at a specific time of day, alongside symptoms and a clinical picture. A service that skips it is not diagnosing anything.

Ongoing monitoring is equally structural. Testosterone therapy is typically long-term and affects markers that need watching, which is why a legitimate service builds retesting into the plan rather than treating the first prescription as the finish line.

Testosterone is a Schedule III controlled substance federally. Prescribing controlled substances remotely is governed by federal rules that have historically required an in-person evaluation, subject to telemedicine exceptions that have been extended repeatedly in recent years.

The current position has a date on it. DEA, jointly with HHS, issued a further temporary extension of the COVID-19 telemedicine flexibilities for prescription of controlled medications, published in the Federal Register at the end of December 2025 under Docket No. DEA-407. That rule took effect on 1 January 2026 and runs through 31 December 2026.

In plain terms: the ability to prescribe testosterone remotely without a prior in-person evaluation currently rests on a temporary rule that expires at the end of 2026. It has been extended repeatedly before, and a special registration framework has been proposed separately, so an extension or a replacement is plausible — but neither is in force today and we are not going to predict which happens.

That position has been genuinely unsettled, and it is the one area where we would tell you to confirm the current state of play rather than trust any page — including this one — to be current. Ask the clinic directly what authority they prescribe under and whether an in-person visit is required for you.

State law adds a second layer. Who may prescribe, whether a nurse practitioner can do so independently, and what the clinician-patient relationship requires all vary by state. Our state pages cover that layer for the markets we have researched.

• Does it require bloodwork before prescribing, and does it use its own ordered labs rather than accepting whatever you send?
• Will you speak to a licensed clinician, and can you find out who they are and where they are licensed?
• Is retesting scheduled, and is it included or billed separately?
• Is the pharmacy named, and is it a licensed pharmacy rather than an unnamed partner?
• What happens if your results do not support a prescription — is there a path that ends in "this is not appropriate for you"?
• Is the total monthly cost stated in writing, including labs and consultations?

That last question matters more than it looks. A service with no honest no is not running a clinical process.

Every service will claim all of the above. What separates them in practice is which of these they treat as load-bearing and which they treat as marketing, and there is a rough order of importance worth applying.

First, whether the service orders its own laboratory work rather than accepting whatever you send. This is the single most reliable divider between a clinical service and a storefront, because it is the expensive step and the one a subscription business has the most incentive to skip.

Second, whether there is a named clinician licensed in your state whom you can identify before you pay. "A licensed provider will review your intake" is not the same claim as a name and a licence number.

Third, whether retesting is scheduled rather than offered. Testosterone therapy is typically long-term and affects markers that need watching; a plan that ends at the first prescription is not a plan.

Fourth, price transparency in writing, including labs and consultations, and what the introductory rate becomes. Fifth, and easiest to check, whether the pharmacy is named and licensed rather than an unnamed partner.

A service strong on the first three and vague on the last two is usually a better bet than the reverse. Cheapness bought by removing the laboratory step is not a saving.

People are frequently surprised by how much a properly run first consultation asks for, and being unprepared is the most common reason the process takes longer than advertised.

• A symptom history, including how long and how it started. Vague answers here produce vague assessments.
• A full list of current medicines and supplements, because several interact with this axis.
• Relevant medical history, including anything cardiovascular, anything affecting the liver, and any history of sleep apnoea.
• Whether you may want to father children, now or later. This genuinely changes the clinical conversation and is routinely not asked by weaker services — its absence from an intake is a meaningful signal.
• Laboratory results drawn on the service's own order, usually more than once and at a specified time of day.
• Photo identification, and a shipping address in a state where the prescriber is licensed.

Expect the timing instruction on the blood draw to be specific. Testosterone varies through the day, so a result without its collection context is difficult to interpret — and a service that does not tell you when to attend is not treating the measurement seriously.

Expect, too, that the answer may be no, or may be that something else should be investigated first. Several conditions produce overlapping symptoms and have entirely different management.

If your symptoms are what prompted this, they are worth investigating regardless of what the answer turns out to be — several conditions produce overlapping symptoms and have entirely different management.

Dosing is determined by a licensed provider, and so is the decision about whether to prescribe at all.

How we verify providers

• Federal Register — Fourth Temporary Extension of COVID-19 Telemedicine Flexibilities for Prescription of Controlled Medications (90 FR 61301, Docket No. DEA-407) — retrieved 2026-08-06
• DEA — Controlled Substances Schedules (anabolic steroids, Schedule III) — retrieved 2026-08-06